Beth Blackwood - Senior Scientist (Technology), Translational Oncology/ In vivo Pharmacology

Beth Blackwood

Senior Scientist (Technology), Translational Oncology/ In vivo Pharmacology

"As a translational scientist, I enjoy being an integral part of the essential feedback loop that extends from the lab bench to the clinic and back!"
14
Years at Genentech
27
Publications
3
Awards & Honors

Prior to coming to Genentech in 2004, I worked in target discovery at SUGEN, evaluating novel kinases for their potential as cancer targets. Here at Genentech, my primary role has shifted to that of an in vivo pharmacologist, shepherding early stage research projects through the drug development process, all the way into the clinic. The career transition from basic to applied research has been particularly rewarding in that I enjoy working with passionate and talented cross-functional team members to deliver drugs that will directly benefit patients’ lives.

Featured Publication

Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.

Mol Cancer Ther. 2013 Oct;12(10):1968-80.

Blackwood E, Epler J, Yen I, Flagella M, O'Brien T, Evangelista M, Schmidt S, Xiao Y, Choi J, Kowanetz K, Ramiscal J, Wong K, Jakubiak D, Yee S, Cain G, Gazzard L, Williams K, Halladay J, Jackson PK, Malek S.